Dr. Jacqueline Zummo is a co-founder of Protara and has served as Chief R&D Officer since February 2026. She previously served as Senior Vice President, Chief Scientific Officer since March 2019 and as the Company’s Vice President, Clinical Research and Medical Affairs since November 2017. Dr. Zummo has over 15 years of experience in senior leadership roles in the biopharma industry, with a strong track record of streamlining clinical development programs and driving successful regulatory outcomes. In addition to her work in clinical development, Dr. Zummo has been instrumental in the launch and commercialization of multiple products through strategic relationship building with KOLs, generating HEOR analytics, and communicating real-world value to managed care organizations.
Prior to joining Protara, Dr. Zummo was Assistant Vice President, Medical Affairs at Vyera Pharmaceuticals, LLC, with prior clinical development, operations and medical affairs roles at Alkermes, Inc., Sunovion Pharmaceuticals Inc. and Wyeth Pharmaceuticals Inc. (later acquired by Pfizer, Inc.).
Dr. Zummo holds a BA from Penn State University, an MBA in Healthcare Marketing from Benedictine University, an MPH in Epidemiology from Benedictine University, and a PhD in Global Health Sciences from Nova Southeastern University.
What is Jacqueline Zummo's net worth?
The estimated net worth of Jacqueline Zummo is at least $536.72 thousand as of April 8th, 2026. Dr. Zummo owns 94,827 shares of Protara Therapeutics stock worth more than $536,721 as of May 6th. This net worth approximation does not reflect any other investments that Dr. Zummo may own. Learn More about Jacqueline Zummo's net worth.
How do I contact Jacqueline Zummo?
Has Jacqueline Zummo been buying or selling shares of Protara Therapeutics?
In the last ninety days, Jacqueline Zummo has sold $124,989.08 in Protara Therapeutics stock. Most recently, Jacqueline Zummo sold 1,134 shares of the business's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $5.40, for a transaction totalling $6,123.60. Following the completion of the sale, the insider now directly owns 94,827 shares of the company's stock, valued at $512,065.80. Learn More on Jacqueline Zummo's trading history.
Who are Protara Therapeutics' active insiders?
Are insiders buying or selling shares of Protara Therapeutics?
In the last year, insiders at the sold shares 2 times. They sold a total of 23,732 shares worth more than $124,989.08. The most recent insider tranaction occured on April, 8th when insider Jacqueline Zummo sold 1,134 shares worth more than $6,123.60. Insiders at Protara Therapeutics own 12.5% of the company.
Learn More about insider trades at Protara Therapeutics. Information on this page was last updated on 4/8/2026.
